Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eniluracil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eniluracil overview
Eniluracil is under development for the treatment of metastatic breast cancer, triple-negative breast cancer, HER2 negative breast cancer, hepatocellular carcinoma and pancreatic cancer, metastatic colorectal cancer, gastric cacner and solid tumors. The drug candidate is administered through oral route. It targets dihydropyrimidine dehydrogenase.
It was also under development for non-small cell lung carcinoma, cervical cancer and prostate cancer.
Processa Pharmaceuticals overview
Processa Pharmaceuticals (Processa) is a development-stage pharmaceutical company that focuses on creating pharmacological solutions in the field of oncology. The company’s pipeline products include PCS6422 which treats breast, colorectal, hepatocellular, pancreatic, gastric and other solid tumors; PCS3117 for pancreatic, gall bladder, non-small cell lung and other cancer; PCS11T treats pancreatic, ovarian, lung, colorectal, gastric, cervical and other cancers. The company works closely with the FDA to define a complete development program and out-license the drug before or after the pivotal study. Processa Pharmaceuticals is headquartered in Hanover, Maryland, the US.
For a complete picture of Eniluracil’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
